Immunomic Therapeutics Announces the Appointment of Frances Harrison as Senior Vice President, Regulatory Affairs

ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein)-mediated nucleic acid-based immunotherapy, today announced the appointment of Frances Harrison as Senior Vice President, Regulatory Affairs. Ms. Harrison brings to the company more than 30 years of experience in global regulatory strategies and submissions, interactions, intelligence and advocacy. She succeeds Louise Peltier, Vice President of Regulatory Affairs, who retired on August 31, 2022.

“Fran’s broad experience and deep knowledge in regulatory affairs will be a tremendous asset during a critical time for ITI, as we continue our interactions with the FDA and other key regulatory agencies regarding our clinical programs,” stated William Hearl, Ph.D., Immunomic Therapeutics’ Chief Executive Officer. “On behalf of the management team, I am pleased to welcome Ms. Harrison to ITI. Being able to attract someone with so much collective experience, which has resulted in more than 75 regulatory submissions operating in 125 countries, is a real coup for ITI. I would also like to take the opportunity to sincerely thank Louise Peltier for her leadership over the last seven years and wish her well in her retirement.”

“I am both honored and excited to be joining Immunomic Therapeutics at such a critical point in its growth cycle,” said Ms. Harrison. “The work and relationships that Louise has fostered over the years position us for successful meetings in the future and I look forward to contributing meaningfully to the company’s future regulatory interactions to further advance ITI’s development programs utilizing the innovative and proprietary UNITE® technology platform.”

Prior to joining ITI, Ms. Harrison worked as a consultant for various biotechnology companies focused on oncology and infectious disease, leading client interactions with global regulatory authorities regarding product approvals and regulatory planning and implementation. Previously, Ms. Harrison served as Senior Vice President, Global Regulatory Affairs and Compliance at BTG International (now Boston Scientific). Prior to her role at BTG, she held senior regulatory positions at a variety of companies specializing in therapeutics for oncology, respiratory, neurology, regenerative medicine, orthopedics and cardiovascular disease including Life Cell Corporation (Allergan), Alphatec Spine, Covidien (Medtronic), Lumenis LTD, and C.R. Bard (Becton, Dickinson and Company).

Ms. Harrison earned a Bachelor of Science in Biochemistry from San Diego State University.

About Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE®), which is designed to utilize the body’s natural biochemistry to develop vaccines that generate broad immune responses. UNITE® has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy, and autoimmune diseases. ITI is primarily focused on applying the UNITE® platform to oncology, where it could potentially have broad applications, including antigen-derived antibodies as biologics. The Company has built a pipeline leveraging UNITE® with programs in oncology, animal health, infectious disease, and allergy. ITI maintains its headquarters in Rockville, Maryland. For more information, please visit www.immunomix.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005006/en/

ITI Company:
Melissa Kemp
[email protected]
301-968-3501

ITI Media:
Melody Carey
[email protected]
917-322-2571

Source: Immunomic Therapeutics, Inc.

You May Also Be Interested In

• Inszone Insurance Services Strengthens Health Care Division with Acquisition of Talerity, LLC
• Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
• RapidFlight Delivers UAS Innovation, Meeting Replicator Initiative Requirements